Levitra Side Effects
In compiling information on side effects, over 4430 men were given Levitra worldwide in controlled and non-controlled clinical trials. The average age was 56 and the age range was 18 to 89. 2200 patients were treated for at least 6 months, 880 patients were treated for at least a year. The most common adverse side effects were headache, flushing, rhinitis, dyspepsia, sinusitis, flu like symptoms, dizziness, increased creatine kinase, and nausea. Back pain was reported by 2% of patients taking Levitra compared to 1.7% in the placebo group.
Uncommon Side Effects
Uncommon (less than 2% of the population) side effects that were reported include: anaphylatic reations, asthenia, face edema, pain, tinnitus, angina pectoris, chest pain, hypertension, hypotension, myocardial ischemia, myocardial infarction, palpitation, postural hypotension, syncope, tachycardia, abdominal pain, abnormal liver function tests, diarrhea, dry mouth, dysphagia, esophagitis, gastritis, gastroesophageal reflux, GGTP increase, vomiting, arthralgia, back pain, myalgia, neck pain, hypertonia, hypesthesia, insomnia, parathesia, somnolence, vertigo, dyspnea, epistaxis, pharyngitis, photosensitivity reaction, pruritus, rash, sweating, abnormal vision, blurred vision, chromatopsia, changes in color vision, conjunctivitis, dim vision, eye pain, glaucoma, photophobia, watery eyes, abnormal ejacualtion, and priapism. This information was summarized from the Levitra document provided at Levitra.com.
NAOIN
NAION (Non-arteritic anterior ischemic optic neuropathy) is caused by a sudden block in the optic nerve due to increased blood flow and is a medical condition of the eye. The optic nerve swells leading to rapid loss in vision though there might not be any pain.
This condition has been reported in association with the use of PDE5 inhibitors including Levitra, but in most, not all, of these cases have included other underlying anatomic or vascular risk factors in developing NAOIN. These include but are not limited to age over 50, low cup to disc ratio, hypertension, diabetes, coronary artery disease, heyperlipidemia, and smoking. It has not been determined whether NAOIN or other visual distrubances are realted directly to use of PD5E inhibitors, or to the patient's other risk factors, or some combination of the factors. Again, please express any concerns you have with your doctor.
Disclaimer
This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.
